← Back to Investors

EQT Life Sciences (formerly LSP)

EQT Life Sciences (formerly Life Sciences Partners/LSP) is one of Europe's leading life sciences venture capital firms. Now part of EQT Group, they invest across the full life cycle of healthcare companies, from early-stage biotech to growth-stage therapeutics and medical technology.

Location
Munich, Germany
Founded
1989
AUM
€3B+
Investment Range
€5M - €100M+
Focus
biotech-focused
Fund Stages
seed, series-a, series-b, series-c, growth

Investment Thesis

EQT Life Sciences invests in innovative healthcare companies with transformative potential. They focus on therapeutics, medical devices, and diagnostics across Europe and globally, bringing deep scientific expertise and the resources of EQT's global platform to portfolio companies.

Team

Partners / Managing Directors (Health & Bio Focus)

  • Martijn Kleijwegt - Partner
  • Joachim Rothe - Partner
  • René Kuijten - Partner

Other Key Team Members

  • Large team of investment professionals across Europe

Focus Areas

  • Therapeutics (oncology, rare diseases, immunology)
  • Medical devices
  • Diagnostics
  • Drug delivery
  • European biotech
  • Global healthcare

Notable Exits

  • argenx - IPO (2017, continued investment, autoimmune diseases)
  • Galapagos - Public company (inflammation)
  • Cerenis - IPO
  • Ablynx - Acquired by Sanofi (2018, $4.8B)

Sources